PRME
NASDAQ · Biotechnology
Prime Medicine Inc
$3.12
-0.02 (-0.64%)
Open$3.13
Previous Close$3.14
Day High$3.17
Day Low$3.05
52W High$6.94
52W Low$2.67
Volume—
Avg Volume2.80M
Market Cap558.64M
P/E Ratio—
EPS$-1.09
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+1,284.3% upside
Current
$3.12
$3.12
Target
$43.19
$43.19
$33.60
$43.19 avg
$71.66
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.55M | 5.54M | 80.41M |
| Net Income | -241,322,095 | -327,047,779 | -21,315,556 |
| Profit Margin | -4,342.4% | -6,238.3% | -26.5% |
| EBITDA | -241,197,159 | -345,948,669 | -26,154,771 |
| Free Cash Flow | — | — | -13,660,015 |
| Rev Growth | — | -17.0% | +23.7% |
| Debt/Equity | — | — | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.48 | +0.20% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $393.16 | +1.95% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.56 | +0.30% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $510.72 | +0.47% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $798.17 | +1.70% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $244.32 | +1.99% | 40.0 | 32.33B |